Tabula Rasa Sees Better Than Expected Q2 Sales, Just As Investor Calls For Removal Of Top Executives

0
19

  • Tabula Rasa HealthCare Inc (NASDAQ: TRHC) expects Q2 sales of $72 – $73 million, exceeding the prior guidance range of $66 – $69 million and the consensus of $67.61 million.
  • Gordon Tunstall, TRHC's Lead Independent Director, said that the Board and management team have spoken with Indaba Capital Management …

Full story available on Benzinga.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here